Modern achievements of interventional cardiology in treatment of coronary heart disease (CHD) have significantly increased frequency of interventions and volume of contrast media (CM). Contrast-induced acute kidney injury (CIAKI) associated with CM administration is determined by 26.5 μmol/l increase in serum creatinine (SCr) within 48 - 72 hours or >？1.5-fold SCr increase versus its known or estimated level in the previous 7 days. Without effective disease management, prevention with early CIAKI risk stratification and cessation of nephrotoxic medications taken by patients are important. Given significant complexity in existing CIAKI treatment, modern therapeutic options are limited only to adequate renal injury prevention. The problem’s significance and diagnostic limitations associated with SCr definition require search for clinically and diagnostically significant AKI biomarkers. In terms of coronarography and percutaneous coronary interventions, several studies have been conducted on clinical and diagnostic significance of some biomarkers. This article characterizes and discloses prospective practical use of neutrophil gelatinase-associated lipocalin (NGAL), liver-type fatty acid binding protein (L-FABP), kidney injury molecule-1 (KIM-1), cystatin C (CysC) and interleukins-6,8,18 (IL-6,8,18) in interventional cardiology.
References
[1]
Alekyan, B.G., et al. (2018) Endovascular Diagnostics and Treatment in the Russian Federation-2017. Endovascular Surgery, 2, 93-240.
[2]
McCullough, P.A., et al. (2016) Contrast-Induced Acute Kidney Injury. Journal of the American College of Cardiology, 68, 1465-1473.
[3]
Gami, A.S. and Garovic, V.D. (2004) Contrast Nephropathy after Coronary Angiography. Mayo Clinic Proceedings, 79, 211-219. https://doi.org/10.4065/79.2.211
[4]
Mehran, R. and Nikolsky, E. (2006) Contrast-Induced Nephropathy: Definition, Epidemiology, and Patients at Risk. Kidney International, 69, S11-S15.
https://doi.org/10.1038/sj.ki.5000368
[5]
McCullough, P.A. (2008) Contrast-Induced Acute Kidney Injury. Journal of the American College of Cardiology, 51, 1419-1428.
https://doi.org/10.1016/j.jacc.2007.12.035
[6]
Persson, P., Hansell, P. and Liss, P. (2005) Pathophysiology of Contrast Medium-Induced Nephropathy. Kidney International, 68, 14-22.
https://doi.org/10.1111/j.1523-1755.2005.00377.x
[7]
Heyman, S.N., Rosenberger, C. and Rosen, S. (2005) Regional Alterations in Renal Haemodynamics and Oxygenation: A Role in Contrast Medium-Induced Nephropathy. Nephrology Dialysis Transplantation, 20, 6-11.
[8]
Mccullough, P.A. and Soman, S.S. (2005) Contrast-Induced Nephropathy. Critical Care Clinics, 21, 261-280. https://doi.org/10.1016/j.ccc.2004.12.003
[9]
Nash, K., Hafeez, A. and Hou, S. (2002) Hospital-Acquired Renal Insufficiency. American Journal of Kidney Diseases, 39, 930-936.
https://doi.org/10.1053/ajkd.2002.32766
[10]
Mehran, R., et al. (2004) A Simple Risk Score for Prediction of Contrast-Induced Nephropathy after Percutaneous Coronary Intervention: Development and Initial Validation. Journal of the American College of Cardiology, 44, 1393-1399.
https://doi.org/10.1016/S0735-1097(04)01445-7
[11]
Aspelin, P., et al. (2003) Nephrotoxic Effects in High-Risk Patients Undergoing Angiography. The New England Journal of Medicine, 348, 491-499.
https://doi.org/10.1056/NEJMoa021833
[12]
Lautin, M., et al. (1991) Radiocontrast-Associated Dysfunction: Incidence Renal and Risk Factors. American Journal of Roentgenology, 157, 49-58.
https://doi.org/10.2214/ajr.157.1.2048539
[13]
Gafarov, V.V., Gromova, E.A., Panov, D.O., Gagulin, I.V. and Gafarova, A.V. (2017) High Prevalence of Anxiety and 15-Year Cardiovascular Risk in Russia/Siberia Inhabitants (Who Framework “Monica-Psychosocial”). Russian Journal of Cardiology, 1, 106-113. (In Russia)
https://doi.org/10.15829/1560-4071-2017-1-106-113
[14]
Stevens, P.E., et al. (2007) Chronic Kidney Disease Management in the United Kingdom: NEOERICA Project Results. Kidney International, 72, 92-99.
https://doi.org/10.1038/sj.ki.5002273
[15]
Narula, A., et al. (2014) Contrast-Induced Acute Kidney Injury after Primary Percutaneous Coronary Intervention: Results from the HORIZONS-AMI Substudy. European Heart Journal, 35, 1533-1540. https://doi.org/10.1093/eurheartj/ehu063
[16]
Caixeta, A., Nikolsky, E. and Mehran, R. (2009) Prevention and Treatment of Contrast-Associated Nephropathy in Interventional Cardiology. Current Cardiology Reports, 11, 377-383. https://doi.org/10.1007/s11886-009-0052-6
[17]
McCullough, P.A., et al. (2006) Risk Prediction of Contrast-Induced Nephropathy. The American Journal of Cardiology, 98, 27-36.
https://doi.org/10.1016/j.amjcard.2006.01.022
[18]
Solomon, R.J., et al. (2009) Contrast-Induced Nephropathy and Long-Term Adverse Events: Cause and Effect? Clinical Journal of the American Society of Nephrology, 4, 1162-1169. https://doi.org/10.2215/CJN.00550109
[19]
Giacoppo, D., et al. (2015) Impact of Contrast-Induced Acute Kidney Injury after Percutaneous Coronary Intervention on Short- and Long-Term Outcomes: Pooled Analysis from the HORIZONS-AMI and ACUITY Trials. Circulation: Cardiovascular Interventions, 8, 1-9.
https://doi.org/10.1161/CIRCINTERVENTIONS.114.002475
[20]
Parfrey, P. (2005) The Clinical Epidemiology of Contrast-Induced Nephropathy. CardioVascular and Interventional Radiology, 28, S3-S11.
https://doi.org/10.1007/s00270-005-0196-8
[21]
James, M.T., et al. (2011) Associations between Acute Kidney Injury and Cardiovascular and Renal Outcomes after Coronary Angiography. Circulation, 123, 409-416. https://doi.org/10.1161/CIRCULATIONAHA.110.970160
[22]
Maioli, M., et al. (2008) Sodium Bicarbonate Versus Saline for the Prevention of Contrast-Induced Nephropathy in Patients with Renal Dysfunction Undergoing Coronary Angiography or Intervention. Journal of the American College of Cardiology, 52, 599-604. https://doi.org/10.1016/j.jacc.2008.05.026
[23]
Weisbord, S.D., et al. (2017) Outcomes after Angiography with Sodium Bicarbonate and Acetylcysteine. The New England Journal of Medicine, 378, 603-614.
https://doi.org/10.1056/NEJMoa1710933
[24]
Su, X., et al. (2017) Comparative Effectiveness of 12 Treatment Strategies for Preventing Contrast-Induced Acute Kidney Injury: A Systematic Review and Bayesian Network Meta-Analysis. American Journal of Kidney Diseases, 69, 69-77.
https://doi.org/10.1053/j.ajkd.2016.07.033
[25]
Wang, N., Qian, P., Kumar, S., Yan, T.D. and Phan, K. (2016) The Effect of N-Acetylcysteine on the Incidence of Contrast-Induced Kidney Injury: A Systematic Review and Trial Sequential Analysis. International Journal of Cardiology, 209, 319-327. https://doi.org/10.1016/j.ijcard.2016.02.083
[26]
Van der Molen, A.J., et al. (2018) Post-Contrast Acute Kidney Injury—Part 1: Definition, Clinical Features, Incidence, Role of Contrast Medium and Risk Factors: Recommendations for Updated ESUR Contrast Medium Safety Committee Guidelines. European Radiology, 28, 2845-2855.
https://doi.org/10.1007/s00330-017-5246-5
[27]
Van Der Molen, A.J., et al. (2018) Post-Contrast Acute Kidney Injury. Part 2: Risk Stratification, Role of Hydration and Other Prophylactic Measures, Patients Taking Metformin and Chronic Dialysis Patients. European Radiology, 28, 2856-2869.
[28]
Khwaja, A. (2012) KDIGO Clinical Practice Guidelines for Acute Kidney Injury. Nephron Clinical Practice, 120, 179-184. https://doi.org/10.1159/000339789
[29]
Fliser, D., et al. (2012) A European Renal Best Practice (ERBP) Position Statement on the Kidney Disease Improving Global Outcomes (KDIGO) Clinical Practice Guidelines on Acute Kidney Injury: Part 1: Definitions, Conservative Management and Contrast-Induced Nephropathy. Nephrology Dialysis Transplantation, 27, 4263-4272. https://doi.org/10.1093/ndt/gfs375
[30]
Volgina, G.V., Kozlovskaya, N.L. and Schekochikhin, L.Y. (2015) Clinical Recommendation for Prophylactic, Diagnosis and Treatment of Contrast-Induced Nephropathy [Electronic Resource]. Russia Scientific Association of Nephrology, Russian Nephrologists Association, 1-18. (In Russian)
[31]
Brar, S.S., et al. (2014) Haemodynamic-Guided Fluid Administration for the Prevention of Contrast-Induced Acute Kidney Injury: The POSEIDON Randomised Controlled Trial. The Lancet, 383, 1814-1823.
https://doi.org/10.1016/S0140-6736(14)60689-9
[32]
Nijssen, E.C., et al. (2017) Prophylactic Hydration to Protect Renal Function from Intravascular Iodinated Contrast Material in Patients at High Risk of Contrast-Induced Nephropathy (AMACING): A Prospective, Randomised, Phase 3, Controlled, Open-Label, Non-Inferiority Trial. The Lancet, 389, 1312-1322.
https://doi.org/10.1016/S0140-6736(17)30057-0
[33]
Jorres, A., et al. (2013) A European Renal Best Practice (ERBP) Position Statement on the Kidney Disease Improving Global Outcomes (KDIGO) Clinical Practice Guidelines on Acute Kidney Injury: Part 2: Renal Replacement Therapy. Nephrology Dialysis Transplantation, 28, 2940-2945. https://doi.org/10.1093/ndt/gft297
[34]
Andreucci, M., Faga, T., Pisani, A., Sabbatini, M. and Michael, A. (2014) Acute Kidney Injury by Radiographic Contrast Media: Pathogenesis and Prevention. BioMed Research International, 2014, Article ID: 362725.
https://doi.org/10.1155/2014/362725
[35]
McCullough, P.A., Bertrand, M.E., Brinker, J.A. and Stacul, F. (2006) A Meta-Analysis of the Renal Safety of Isosmolar Iodixanol Compared With Low-Osmolar Contrast Media. Journal of the American College of Cardiology, 48, 692-699.
https://doi.org/10.1016/j.jacc.2006.02.073
[36]
Solomon, R. (2005) The Role of Osmolality in the Incidence of Contrast-Induced Nephropathy: A Systematic Review of Angiographic Contrast Media in High Risk Patients. Kidney International, 68, 2256-2263.
https://doi.org/10.1111/j.1523-1755.2005.00684.x
[37]
Mehran, R., et al. (2009) Ionic Low-Osmolar versus Nonionic Iso-Osmolar Contrast Media to Obviate Worsening Nephropathy after Angioplasty in Chronic Renal Failure Patients. Journal of the American College of Cardiology, 2, 415-421.
https://doi.org/10.1016/j.jcin.2009.03.007
[38]
Solomon, R. (2009) Preventing Contrast-Induced Nephropathy: Problems, Challenges and Future Directions. BMC Medicine, 7, Article No. 24.
https://doi.org/10.1186/1741-7015-7-24
[39]
Gurm, H.S., et al. (2012) Contemporary Use and Effectiveness of N-Acetylcysteine in Preventing Contrast-Induced Nephropathy among Patients Undergoing Percutaneous Coronary Intervention. Journal of the American College of Cardiology, 5, 98-104. https://doi.org/10.1016/j.jcin.2011.09.019
[40]
Waikar, S.S. and Bonventre, J.V. (2009) Creatinine Kinetics and the Definition of Acute Kidney Injury. Journal of the American Society of Nephrology, 20, 672-679.
[41]
Murray, P.T., et al. (2014) Potential Use of Biomarkers in Acute Kidney Injury: Report and Summary of Recommendations from the 10th Acute Dialysis Quality Initiative Consensus Conference. Kidney International, 85, 513-521.
https://doi.org/10.1038/ki.2013.374
[42]
Endre, Z.H. and Pickering, J.W. (2013) Biomarkers and Creatinine in AKI: The Trough of Disillusionment or the Slope of Enlightenment? Kidney International, 84, 644-647. https://doi.org/10.1038/ki.2013.168
[43]
Lichosik, M., et al. (2015) Interleukin 18 and Neutrophil-Gelatinase Associated Lipocalin in Assessment of the Risk of Contrast-Induced Nephropathy in Children. Central European Journal of Immunology, 40, 447-453.
https://doi.org/10.5114/ceji.2015.56967
[44]
Haase, M. and Mertens, P.R. (2010) Urinary Biomarkers-Silver Bullets to Faster Drug Development and Nephron Protection. Nephrology Dialysis Transplantation, 25, 3167-3169. https://doi.org/10.1093/ndt/gfq504
[45]
Bachorzewska-Gajewska, H., et al. (2007) Could Neutrophil-Gelatinase-Associated Lipocalin and Cystatin C Predict the Development of Contrast-Induced Nephropathy after Percutaneous Coronary Interventions in Patients with Stable Angina and Normal Serum Creatinine Values? Kidney and Blood Pressure Research, 30, 408-415. https://doi.org/10.1159/000109102
[46]
Malyszko, J., Bachorzewska-Gajewska, H., Poniatowski, B., Malyszko, J.S. and Dobrzycki, S. (2009) Urinary and Serum Biomarkers after Cardiac Catheterization in Diabetic Patients with Stable Angina and without Severe Chronic Kidney Disease. Renal Failure, 31, 910-919. https://doi.org/10.3109/08860220903216113
[47]
Bachorzewska-Gajewska, H., Poniatowski, B. and Dobrzycki, S. (2009) NGAL (Neutrophil Gelatinase-Associated Lipocalin) and L-FABP after Percutaneous Coronary Interventions Due to Unstable Angina in Patients with Normal Serum Creatinine. Advances in Medical Sciences, 54, 221-224.
[48]
Ling, W., Zhaohui, N., Ben, H., Leyi, G., Jianping, L., Huili, D. and Jiaqi, Q. (2008) Urinary IL-18 and NGAL as Early Predictive Biomarkers in Contrast-Induced Nephropathy after Coronary Angiography. Nephron Clinical Practice, 108, c176-c181.
https://doi.org/10.1159/000117814
[49]
Qureshi, A.C., et al. (2011) Serum NGAL Identifies Contrast Nephropathy Early in Patients with Diabetes Mellitus and Chronic Kidney Disease Undergoing Coronary Angiography and Angioplasty. Heart, 97, 17-18.
[50]
McMahon, B.A. and Murray, P.T. (2010) Urinary Liver Fatty Acid-Binding Protein: Another Novel Biomarker of Acute Kidney Injury. Kidney International, 77, 657-659. https://doi.org/10.1038/ki.2010.5
[51]
Portilla, D., et al. (2008) Liver Fatty Acid-Binding Protein as a Biomarker of Acute Kidney Injury after Cardiac Surgery. Kidney International, 73, 465-472.
https://doi.org/10.1038/sj.ki.5002721
[52]
Doi, K., Noiri, E. and Sugaya, T. (2011) Urinary L-Type Fatty Acid-Binding Protein as a New Renal Biomarker in Critical Care. Current Opinion in Critical Care, 16, 545-549. https://doi.org/10.1097/MCC.0b013e32833e2fa4
[53]
Manabe, K., et al. (2012) Urinary Liver-Type Fatty Acid-Binding Protein Level as a Predictive Biomarker of Contrast-Induced Acute Kidney Injury. European Journal of Clinical Investigation, 42, 557-563.
https://doi.org/10.1111/j.1365-2362.2011.02620.x
[54]
Nakamura, T., et al. (2006) Urinary Excretion of Liver-Type Fatty Acid-Binding Protein in Contrast Medium-Induced Nephropathy. American Journal of Kidney Diseases, 47, 439-444. https://doi.org/10.1053/j.ajkd.2005.11.006
[55]
Kato, K., et al. (2008) Valuable Markers for Contrast-Induced Nephropathy in Patients Undergoing Cardiac Catheterization. Circulation Journal, 72, 1499-1505.
https://doi.org/10.1253/circj.CJ-07-1006
[56]
Belcher, J.M., Edelstein, C.L. and Parikh, C.R. (2011) Clinical Applications of Biomarkers for Acute Kidney Injury. American Journal of Kidney Diseases, 57, 930-940. https://doi.org/10.1053/j.ajkd.2010.11.032
[57]
Stacul, F., et al. (2006) Strategies to Reduce the Risk of Contrast-Induced Nephropathy. The American Journal of Cardiology, 98, 59-77.
https://doi.org/10.1016/j.amjcard.2006.01.024
[58]
Han, W.K., Bailly, V., Abichandani, R., Thadhani, R. and Bonventre, J.V. (2002) Kidney Injury Molecule-1 (KIM-1): A Novel Biomarker for Human Renal Proximal Tubule Injury. Kidney International, 62, 237-244.
https://doi.org/10.1046/j.1523-1755.2002.00433.x
[59]
Waanders, F., van Timmeren, M.M., Stegeman, C.A., Bakker, S.J.L. and van Goor, H. (2010) Kidney Injury Molecule-1 in Renal Disease. The Journal of Pathology, 220, 7-16. https://doi.org/10.1002/path.2642
[60]
Barrett, A.J., Davies, M.E. and Grubb, A. (1984) The Place of Human γ-Trace (Cystatin C) amongst the Cysteine Proteinase Inhibitors. Biochemical and Biophysical Research Communications, 120, 631-636.
https://doi.org/10.1016/0006-291X(84)91302-0
[61]
Grubb, A.O. (2001) Cystatin C-Properties and Use as Diagnostic Marker. Advances in Clinical Chemistry, 35, 63-99. https://doi.org/10.1016/S0065-2423(01)35015-1
[62]
Proletov, Y.Y., Saganova, E.S. and Smirnov, A.V. (2014) Biomarkers in the Diagnosis of Acute Kidney Injury. Communication I. Nephrology, 18, 25-35.
[63]
Zhu, J., et al. (2006) Cystatin C as a Reliable Marker of Renal Function Following Heart Valve Replacement Surgery with Cardiopulmonary Bypass. Clinica Chimica Acta, 374, 116-121. https://doi.org/10.1016/j.cca.2006.06.001
[64]
Vanmassenhove, J., Vanholder, R., Nagler, E. and Van Biesen, W. (2013) Urinary and Serum Biomarkers for the Diagnosis of Acute Kidney Injury: An in-Depth Review of the Literature. Nephrology Dialysis Transplantation, 28, 254-273.
https://doi.org/10.1093/ndt/gfs380
[65]
Melnikov, V.Y., et al. (2001) Impaired IL-18 Processing Protects Caspase-1-Deficient Mice from Ischemic Acute Renal Failure. Journal of Clinical Investigation, 107, 1145-1152. https://doi.org/10.1172/JCI12089
[66]
He, H., et al. (2014) Urinary Interleukin 18 as an Early Indicator to Predict Contrast Induced Nephropathy in Patients Undergoing Percutaneous Coronary Intervention. Experimental and Therapeutic Medicine, 8, 1263-1266.
https://doi.org/10.3892/etm.2014.1898
[67]
Che, M., et al. (2010) Clinical Usefulness of Novel Biomarkers for the Detection of Acute Kidney Injury Following Elective Cardiac Surgery. Nephron Clinical Practice, 115, с66-с72. https://doi.org/10.1159/000286352
[68]
Proletov, Y.Y., Saganova, E.S. and Smirnov, A.V. (2014) Biomarkers in the Diagnosis of Acute Kidney Injury. Communication II. Nephrology, 18, 51-58.
